The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Rising one place to number one overall, the British drugmaker has overtaken the NHS as the preferred destination for science ...

The strategies that the industry’s lobbyists use, or don’t deploy, matter as the Trump administration moves more decisively ...

LONDON, GREATER LONDON, UNITED KINGDOM, July 4, 2025 /EINPresswire.com/ -- The castration-resistant prostate cancer CRPC or hormone-refractory prostate cancer HRPCA therapeutics market has exhibited ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on PD-1xVEGF bispecific ivonescimab that is estimated to be worth as much as ...

Pfizer’s new products/late-stage pipeline candidates and newly acquired products, including those acquired from Seagen, ...

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone ...

Results of two phase 2 studies suggest efgartigimod could be a potential treatment for myositis and Sjögren disease in ...

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

Starboard Value has gained a reputation for pushing for changes such as new CEOs and cost cuts by acquiring significant ...

Both TEGSEDI and WAYLIVRA are legacy assets that were originally brought to the EU market via an Ionis subsidiary, Akcea ...